Search Results

InventisBio Co., Ltd., a clinical-stage biotech company based in Shanghai, China has published the clinical data of their oral KRAS G12C inhibitor D-1553, for the first time in cancer patients.

InventisBio, a clinical stage biotech company dedicated to the research and development of innovative small molecule drugs, announced the recent completion of a $147 million series D financing which has attracted participation of many top biopharmaceutical and healthcare venture capital funds.

InventisBio (Shanghai) (hereinafter referred to as “InventisBio”) announced today that it has signed a “Collaboration Agreement” with Betta Pharma (hereinafter referred to as “Betta Pharma”)

InventisBio Inc., a clinical stage biotech company, announced the closing of a $70 million USD Series C financing in January 2019.

Starting with just $11 million seed in 2015, investors have proven their faith in InvestiBio with their increasing financial support.

Hundreds of presentations on oncology research are highlighted at the AACR Annual Meeting, which is running from April 7 to 13 in New Orleans.

BridGene Biosciences, Inc., a biotechnology company leveraging a proprietary chemoproteomic platform to discover and develop small-molecule drugs for high-value, traditionally undruggable targets, today announced the completion of a $38.5 million Series B financing by Lapam Capital, Junson Capital and Dyee Capital.

According to Coherent Market Insights, the Asia gout disease treatment market is estimated to be valued at US$ 643.5 Mn in 2020 and is expected to exhibit a CAGR of 9.1% during the forecast period (2020-2027). Key Trends and Analysis of the Asia Gout Disease Treatment Market: Market players are focused on adoption of inorganic growth strategies such as acquisitions, collaborations, and partnerships to strengthen